-
Case Studies
Subscription Travel Platforms – Case Study
Subscription Travel Platforms Report Overview The subscription travel platforms report analyzes the importance of travel subscription platforms across multiple sectors within the tourism industry, including airlines, hotels, and online travel agents (OTAs). The report also includes market trends, opportunities, and challenges subscription-based travel platforms endure in the tourism sector. The basic premise of a subscription model is that customers are not just seen as one-off sales but as a long-term investment and recurring revenue model. A few companies integrate subscriptions...
-
Thematic Analysis
Net Zero Strategies in the Mining Sector – Thematic Intelligence
Reasons to buy the ‘Net Zero Strategies in the Mining Sector’ thematic intelligence report: Gain in-depth insight into the net zero targets and performance of key mining companies. Elucidate the importance of a net zero strategy in the mining sector. Analyze the progress made by the leading companies within the theme to achieve their emission target. Analyze the net zero strategies in the mining sector theme to develop effective business plans and gain a competitive edge. How is our ‘Net...
-
Sector Analysis
Malawi Insurance Industry – Key Trends and Opportunities to 2028
Malawi Insurance Market Report Overview The gross written premium of the Malawi insurance market was MWK174.8 billion ($151.2 million) in 2023. The market is expected to achieve a CAGR of more than 15% during 2024-2028. The Malawi insurance market research report provides in-depth market analysis, information, and insights into the Malawi insurance industry. It provides values for key performance indicators such as gross written premium, penetration, premium accepted and ceded, profitability ratios, and premium by line of business, during the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INKmune in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INKmune in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INKmune in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OSSM-007 in Graft Versus Host Disease (GVHD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OSSM-007 in Graft Versus Host Disease (GVHD) Drug Details: OSSM-007Â is under investigation for the prophylaxis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INKmune in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INKmune in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INKmune in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INKmune in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INKmune in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INKmune in Chronic Myelomonocytic Leukemia (CMML) Drug Details: INKmune is...
-
Product Insights
Fragile X Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Fragile X Syndrome - Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Myotonic Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Myotonic Dystrophy - Drugs In Development, 2023’, provides an overview of the Myotonic Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Friedreich Ataxia – Drugs In Development, 2023
Global Markets Direct’s, ‘Friedreich Ataxia - Drugs In Development, 2023’, provides an overview of the Friedreich Ataxia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...